194 related articles for article (PubMed ID: 33052749)
1. Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An
Usmani OS; Mignot B; Kendall I; Maria R; Cocconi D; Georges G; Scichilone N
J Aerosol Med Pulm Drug Deliv; 2021 Jun; 34(3):204-211. PubMed ID: 33052749
[No Abstract] [Full Text] [Related]
2. Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations.
Usmani OS; Scichilone N; Mignot B; Belmans D; Van Holsbeke C; De Backer J; De Maria R; Cuoghi E; Topole E; Georges G
Int J Chron Obstruct Pulmon Dis; 2020; 15():2433-2440. PubMed ID: 33116458
[TBL] [Abstract][Full Text] [Related]
3. Lung Deposition of Inhaled Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide in Healthy Volunteers and Asthma: The STORM Study.
Usmani OS; Baldi S; Warren S; Panni I; Girardello L; Rony F; Taylor G; DeBacker W; Georges G
J Aerosol Med Pulm Drug Deliv; 2022 Aug; 35(4):179-185. PubMed ID: 35128939
[No Abstract] [Full Text] [Related]
4. Ethnic Sensitivity Study of the Extrafine, Single-Inhaler, Triple Therapy Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide Pressurized Metered Dose Inhaler in Japanese and Caucasian Healthy Individuals: A Randomized, Double-Blind, Single-Dose Crossover Study.
Cella M; Täubel J; Delestre-Levai I; Tulard A; Vele A; Georges G
Clin Ther; 2021 Nov; 43(11):1934-1947.e4. PubMed ID: 34600734
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
Zheng J; Baldi S; Zhao L; Li H; Lee KH; Singh D; Papi A; Grapin F; Guasconi A; Georges G
Respir Res; 2021 Mar; 22(1):90. PubMed ID: 33757520
[TBL] [Abstract][Full Text] [Related]
6. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
Virchow JC; Poli G; Herpich C; Kietzig C; Ehlich H; Braeutigam D; Sommerer K; Häussermann S; Mariotti F
J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial.
Beeh KM; Kuna P; Corradi M; Viaud I; Guasconi A; Georges G
Int J Chron Obstruct Pulmon Dis; 2021; 16():79-89. PubMed ID: 33488071
[TBL] [Abstract][Full Text] [Related]
8. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics and safety of a novel extrafine BDP/FF/GB combination delivered via metered-dose inhaler in healthy Chinese subjects.
Hu C; Miao J; Shu S; Wang Y; Zhu X; Luo Z
Eur J Pharm Sci; 2020 Mar; 144():105198. PubMed ID: 31862312
[TBL] [Abstract][Full Text] [Related]
10. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
[TBL] [Abstract][Full Text] [Related]
11. Modeled small airways lung deposition of two fixed-dose triple therapy combinations assessed with in silico functional respiratory imaging.
Usmani O; Li G; De Backer J; Sadafi H; Wu L; Marshall J
Respir Res; 2023 Sep; 24(1):226. PubMed ID: 37742015
[TBL] [Abstract][Full Text] [Related]
12. Treatment response according to small airways disease status: The effects of high-strength extrafine pMDI beclomethasone dipropionate/formoterol fumarate in fixed dose combination in moderate uncontrolled asthmatic patients.
Carpagnano GE; Scioscia G; Lacedonia D; Stornelli SR; Irene Quarato CM; Soccio P; Resta O; Foschino Barbaro MP
Pulm Pharmacol Ther; 2020 Feb; 60():101879. PubMed ID: 31866498
[TBL] [Abstract][Full Text] [Related]
13. The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN).
Skloot GS; Guasconi A; Lavon BR; Georges G; De Backer W; Galkin D; Cortellini M; Panni I; Bates JHT
Respir Res; 2023 Oct; 24(1):244. PubMed ID: 37803368
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers.
Luo Z; Lucci G; Santoro L; Topole E; Mariotti F
Pulm Pharmacol Ther; 2022 Jun; 73-74():102129. PubMed ID: 35525480
[TBL] [Abstract][Full Text] [Related]
15. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.
Van Holsbeke C; De Backer J; Vos W; Marshall J
Ther Adv Respir Dis; 2018; 12():1753466618760948. PubMed ID: 29499614
[TBL] [Abstract][Full Text] [Related]
16. Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease.
Singh D; Corradi M; Spinola M; Petruzzelli S; Papi A
NPJ Prim Care Respir Med; 2016 Jun; 26():16030. PubMed ID: 27309985
[TBL] [Abstract][Full Text] [Related]
17. Comparison of extrafine beclomethasone dipropionate/formoterol fumarate dry powder inhaler and pressurized metered-dose inhaler in Chinese patients with asthma: the FORTUNE study.
Zheng J; Zhang J; Fu X; Lin C; Zhang X; Mei X; Corradi M; Cappellini G; Calabro E; Zhu C; Topole E
J Asthma; 2024 Apr; 61(4):360-367. PubMed ID: 37878325
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Small Airways with Inhaled Corticosteroid/Long-Acting Beta Agonist Dry Powder Inhalers: A Functional Respiratory Imaging Study.
Watz H; Barile S; Guastalla D; Topole E; Cocconi D; Mignot B; Belmans D; Duman D; Poli G; Fabbri LM
J Aerosol Med Pulm Drug Deliv; 2021 Sep; 34(5):280-292. PubMed ID: 33944614
[No Abstract] [Full Text] [Related]
19. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
Singh D; Ciurlia G; Piccinno A; Muraro A; Bocchi M; Scuri M
Pulm Pharmacol Ther; 2017 Feb; 42():43-51. PubMed ID: 28065679
[TBL] [Abstract][Full Text] [Related]
20. Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study.
Rogliani P; Ora J; Girolami A; Rossi I; de Guido I; Facciolo F; Cazzola M; Calzetta L
Pulm Pharmacol Ther; 2021 Aug; 69():102050. PubMed ID: 34129945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
